What question did this study set out to answer?

This study aims to assess the safety of inavolisib combined with ribociclib or abemaciclib and fulvestrant or letrozole in advanced breast cancer patients.

February 19, 2026Clinical Cancer Research

Abstract PD10-08: Interim safety in the inavolisib + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy and safety of multiple treatment combinations in patients with advanced breast cancer

View Full Paper

Ask AI

Bookmark

Authors

EGEinav Nili Gal-Yam YPY. H. ParkSamsung Medical Center ASAmir SonnenblickTel Aviv University

Discussion

Member takes

Implication

Phase 1b/2 study evaluates safety outcomes of treatment combinations in advanced breast cancer, suggesting tolerability of regimens.

Key Points

This study aims to assess the safety of inavolisib combined with ribociclib or abemaciclib and fulvestrant or letrozole in advanced breast cancer patients.
Eligible patients with PIK3CA-mutated, HR+, HER2- advanced breast cancer were randomized into treatment groups.
Patients received inavolisib daily with either ribociclib or abemaciclib and fulvestrant or letrozole.
Adverse events were assessed based on established criteria throughout the study.
Discontinuations due to disease progression were observed in both treatment arms, while no patients in one group discontinued due to progression.
Most patients experienced grade 3 adverse events, primarily from inavolisib combinations.
Some serious adverse events were reported, with hyperglycemia noted as related to inavolisib.

Cite This Study

Gal-Yam et al. (2026) studied this question.

synapsesocial.com/papers/6996a879ecb39a600b3ef3ce https://doi.org/10.1158/1557-3265.sabcs25-pd10-08

View Full Paper

Ask AI

Bookmark

Abstract PD10-08: Interim safety in the inavolisib + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy and safety of multiple treatment combinations in patients with advanced breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PD10-08: Interim safety in the inavolisib + ribociclib or abemaciclib + fulvestrant or letrozole arms of MORPHEUS-pan breast cancer: A Phase 1b/2 study of efficacy and safety of multiple treatment combinations in patients with advanced breast cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider